U-LABA/ICS Effects on Exercise Performance, Indacaterol
Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Indacaterol
Morten Hostrup, PhD
30 participants
Jan 15, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants are administered 125 µg indacaterol + mometasonefluroate
Participants are administered placebo
Participants are administered 500 µg indacaterol + mometasonefluroate
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06067100